Amgen's migraine drug succeeds in late-stage trial
- Record-setting rally pushes on as S&P ends week up 3 percent
- Trump's Cohn Pick Most Bullish Sign Yet for Banks - Cowen
- Unusual 11 Mid-Day Movers: (IDXG) (INVN) (EBS) Higher; (SCON) (DTEA) (DLTH) Lower (more...)
- 21st Century Fox (FOXA) offers to acquire Sky for GBP10.75/share
- Coca Cola (KO) Announces James Quincey to Succeed Muhtar Kent as CEO; Kent to Continue as Chairman
An Amgen sign is seen at the company's office in South San Francisco, California October 21, 2013. REUTERS/Robert Galbraith/File Photo
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
(Reuters) - Amgen Inc (NASDAQ: AMGN) said on Wednesday its migraine treatment met the main goal of reducing monthly migraine days in patients with episodic migraine in a second late-stage study.
Patients receiving 70 milligram of the drug, erenumab, experienced reduction of 3.2 days from baseline in monthly migraine days, while those on 140 milligram experienced reduction of 3.7 days. Those in the placebo experienced a 1.8-day reduction, the company said.
At baseline, patients were experiencing an average of 8.3 migraine days per month, Amgen said.
Amgen, which is co-developing the treatment with Swiss drugmaker Novartis AG (NASDAQ: NOVN), said patients received the injectable drug once monthly for six months.
Erenumab is also being tested for episodic migraine prevention and chronic migraine prevention.
Worldwide, about 90 percent of people diagnosed with migraine have episodic migraine, which is characterized by up to 14 migraine days a month, the company said.
Amgen's shares, which closed at $147.23 in regular trading, were up marginally after market on Wednesday.
(Reporting by Divya Grover in Bengaluru)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gambia refuses entry to ECOWAS head amid election dispute
- Syria, Russia pound rebel-held Aleppo but advances halt
- After impeachment, South Korea prime minister urges calm, vigilance
Create E-mail Alert Related CategoriesFDA, Reuters
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!